ATE530523T1 - (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate - Google Patents

(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate

Info

Publication number
ATE530523T1
ATE530523T1 AT07805287T AT07805287T ATE530523T1 AT E530523 T1 ATE530523 T1 AT E530523T1 AT 07805287 T AT07805287 T AT 07805287T AT 07805287 T AT07805287 T AT 07805287T AT E530523 T1 ATE530523 T1 AT E530523T1
Authority
AT
Austria
Prior art keywords
carbazol
tetrahydro
amino
acetic acid
acid derivatives
Prior art date
Application number
AT07805287T
Other languages
English (en)
Inventor
Heinz Fretz
Julien Pothier
Philippe Risch
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE530523T1 publication Critical patent/ATE530523T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07805287T 2006-08-07 2007-08-02 (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate ATE530523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006052723 2006-08-07
PCT/IB2007/053046 WO2008017989A1 (en) 2006-08-07 2007-08-02 (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives

Publications (1)

Publication Number Publication Date
ATE530523T1 true ATE530523T1 (de) 2011-11-15

Family

ID=38805811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07805287T ATE530523T1 (de) 2006-08-07 2007-08-02 (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate

Country Status (28)

Country Link
US (1) US8143304B2 (de)
EP (2) EP2316824A1 (de)
JP (1) JP5220013B2 (de)
KR (1) KR101411820B1 (de)
CN (1) CN101500996B (de)
AR (1) AR062222A1 (de)
AT (1) ATE530523T1 (de)
AU (1) AU2007282949B8 (de)
BR (1) BRPI0715179A2 (de)
CA (1) CA2658986C (de)
CL (1) CL2007002274A1 (de)
CY (1) CY1112276T1 (de)
DK (1) DK2051962T3 (de)
ES (1) ES2374321T3 (de)
HK (1) HK1130062A1 (de)
HR (1) HRP20120044T1 (de)
IL (1) IL196891A (de)
MA (1) MA30696B1 (de)
MX (1) MX2009001105A (de)
MY (1) MY147588A (de)
NO (1) NO20090979L (de)
NZ (1) NZ574705A (de)
PL (1) PL2051962T3 (de)
PT (1) PT2051962E (de)
RU (1) RU2448092C2 (de)
SI (1) SI2051962T1 (de)
TW (1) TWI408126B (de)
WO (1) WO2008017989A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
DK1833791T3 (da) 2004-12-27 2011-10-24 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
KR101235961B1 (ko) 2008-02-01 2013-02-21 판미라 파마슈티칼스, 엘엘씨 프로스타글란딘 ｄ２ 수용체의 ｎ,ｎ-이치환 아미노알킬비페닐 길항제
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
JP2011526281A (ja) * 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8394819B2 (en) * 2009-02-24 2013-03-12 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists
JP2013500978A (ja) 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの眼の医薬組成物
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
TWI562987B (en) 2010-03-22 2016-12-21 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
EP2697223B1 (de) * 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino-)6,7,8,9-tetrahydropyrido-[1,2-a-]indol-essigsäure-derivate und ihre verwendung als prostaglandin-d2-rezeptor-modulatoren
PL3119779T3 (pl) 2014-03-17 2019-01-31 Idorsia Pharmaceuticals Ltd Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2
JP6484644B2 (ja) 2014-03-18 2019-03-13 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
CN104402798B (zh) * 2014-10-21 2016-09-14 杭州瑞德化工有限公司 一种3-氨基-1，2，3，4-四氢咔唑的拆分方法
WO2016133793A1 (en) 2015-02-16 2016-08-25 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
CN112094223B (zh) * 2019-06-18 2023-09-15 华东师范大学 一类脲基四氢咔唑类小分子有机化合物及用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
US5298626A (en) * 1991-01-18 1994-03-29 Hoechst-Roussel Pharmaceuticals Incorporated Select cyclopent[b]indoles
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5350762A (en) * 1993-03-08 1994-09-27 Hoechst-Roussel Pharmaceuticals Incorporated Tetrahydrocyclopent[B]indole methanamines and related compounds
US6713473B1 (en) * 1999-04-20 2004-03-30 Meiji Seika Kaisha, Ltd. Tricyclic compounds
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
EP1395590B1 (de) 2001-05-23 2006-09-27 Merck Frosst Canada & Co. Dihydropyrrolo¬1,2-a|indol- und tetrahydropyrido¬1,2-a|indolderivate als prostaglandin rezeptor antagonisten
GB2408001B (en) 2001-10-18 2006-03-29 Derek Colin Tolley Filtration of liquid media
AU2002361430B2 (en) * 2001-12-14 2007-09-13 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
WO2003097042A1 (fr) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
GB2388540A (en) * 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2004039807A1 (en) 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine and pyridoindolizine derivatives
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
JP2006528938A (ja) 2003-05-20 2006-12-28 メルク フロスト カナダ リミテツド フルオロ−メタンスルホニル置換シクロアルカノインドール、およびプロスタグランジンｄ２アンタゴニストとしてのこれらの使用
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
CA2527773A1 (en) 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines as dp receptor antagonists
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
WO2005040114A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
PL1718649T3 (pl) 2004-01-31 2009-11-30 Actimis Pharmaceuticals Inc Pochodne kwasu imidazo[1,2-c]pirymidynylooctowego
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
KR101165863B1 (ko) 2004-03-11 2012-07-13 액테리온 파마슈티칼 리미티드 인돌-1-일-아세트산 유도체
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
KR101213912B1 (ko) 2004-08-26 2012-12-18 액테리온 파마슈티칼 리미티드 Ｃｒｔｈ2 길항제로서의2-설파닐-벤조이미다졸-1-일-아세틱 애시드 유도체
WO2006034419A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
US7732618B2 (en) 2004-09-21 2010-06-08 Wyeth Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
DK1833791T3 (da) * 2004-12-27 2011-10-24 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
JP5024039B2 (ja) 2005-02-25 2012-09-12 小野薬品工業株式会社 インドール化合物およびその用途
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
ZA200709819B (en) 2005-05-24 2009-09-30 Serono Lab Tricyclic spiro derivatives as CRTH2 modulators
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP1916245B1 (de) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indolderivat mit pgd2-rezeptor-antagonistischer wirkung
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
EP1931632A4 (de) 2005-08-18 2011-05-11 Microbia Inc Nützliche indolverbindungen
EP1932839A4 (de) 2005-09-06 2014-09-10 Shionogi & Co Indolcarbonsäurederivat mit antagonistischer wirkung am pgd2-rezeptor
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2008017989A1 (en) 2008-02-14
MA30696B1 (fr) 2009-09-01
US8143304B2 (en) 2012-03-27
JP5220013B2 (ja) 2013-06-26
MY147588A (en) 2012-12-31
HRP20120044T1 (hr) 2012-02-29
CA2658986A1 (en) 2008-02-14
CL2007002274A1 (es) 2008-04-18
US20100190830A1 (en) 2010-07-29
EP2051962A1 (de) 2009-04-29
IL196891A0 (en) 2009-11-18
RU2448092C2 (ru) 2012-04-20
KR20090047504A (ko) 2009-05-12
TW200817328A (en) 2008-04-16
CN101500996B (zh) 2012-07-04
AU2007282949B8 (en) 2012-10-04
AR062222A1 (es) 2008-10-22
AU2007282949B2 (en) 2012-08-30
EP2316824A1 (de) 2011-05-04
HK1130062A1 (de) 2009-12-18
JP2010500337A (ja) 2010-01-07
SI2051962T1 (sl) 2012-02-29
PT2051962E (pt) 2012-01-10
RU2009107889A (ru) 2010-09-20
IL196891A (en) 2013-07-31
PL2051962T3 (pl) 2012-03-30
ES2374321T3 (es) 2012-02-15
NO20090979L (no) 2009-05-06
CN101500996A (zh) 2009-08-05
CY1112276T1 (el) 2015-12-09
KR101411820B1 (ko) 2014-06-24
CA2658986C (en) 2014-11-25
MX2009001105A (es) 2009-02-10
NZ574705A (en) 2011-12-22
BRPI0715179A2 (pt) 2013-06-11
AU2007282949A1 (en) 2008-02-14
TWI408126B (zh) 2013-09-11
DK2051962T3 (da) 2012-01-02
EP2051962B1 (de) 2011-10-26

Similar Documents

Publication Publication Date Title
ATE530523T1 (de) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
NL2000537A1 (nl) Aminederivaten.
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
BRPI0810646A2 (pt) " compostos farmacêuticos ".
ATE512135T1 (de) Spiroindolinonderivate
ATE487691T1 (de) Acetylenderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
NL1029250A1 (nl) Benzimidazoloncarbonzuurderivaten.
NO20085127L (no) Leptomycinderivater
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
CR10353A (es) Nuevos compuestos.
NL2000527A1 (nl) Dibenzylamine-verbindingen en -derivaten.
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2051962

Country of ref document: EP